Tsui Teresa C O, Trudeau Maureen E, Mitsakakis Nicholas, Krahn Murray D, Davis Aileen M
Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, Ontario, Canada.
Canadian Centre for Applied Research in Cancer Control.
MDM Policy Pract. 2022 Dec 8;7(2):23814683221142267. doi: 10.1177/23814683221142267. eCollection 2022 Jul-Dec.
. Generic preference-based instruments inadequately measure breast cancer (BrC) health-related quality-of-life preferences given advances in therapy. Our overall purpose is to develop the Breast Utility Instrument (BUI), a BrC-specific preference-based instrument. This study describes the selection of the BUI items. A total of 408 patients from diverse BrC health states completed the EORTC QLQ-C30 and BR45 (breast module). For each of 10 dimensions previously assessed with confirmatory factor analysis, we evaluated data fit to the Rasch model based on global model and item fit, including threshold ordering, item residuals, infit and outfit, differential item functioning (age), and unidimensionality. Misfitting items were removed iteratively, and the model fit was reassessed. From items fitting the Rasch model, we selected 1 item per dimension based on high patient- and clinician-rated item importance, breadth of item thresholds, and clinical relevance. Global model fit was good in 7 and borderline in 3 dimensions. Separation index was acceptable in 4 dimensions. Item selection criteria were maximized for the following items: 1) physical functioning (trouble taking a long walk), 2) emotional functioning (worry), 3) social functioning (interfering with social activities), 4) pain (having pain), 5) fatigue (tired), 6) body image (dissatisfied with your body), 7) systemic therapy side effects (hair loss), 8) sexual functioning (interest in sex), 9) breast symptoms (oversensitive breast), and 10) endocrine therapy symptoms (problems with your joints). . We propose 10 items for the BUI. Our next steps include assessing the measurement properties prior to eliciting preference weights of the BUI.
A previous confirmatory factor analysis established 10 dimensions of the European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30) and its breast module (BR45).In this study, we selected 1 item per dimension based on fit to the Rasch model, patient- and clinician-rated item importance, breadth of item thresholds, and clinical relevance.These items form the core of the future Breast Utility Instrument (BUI).The future BUI will be a novel breast cancer-specific preference-based instrument that potentially will better reflect women's preferences in clinical decision making and cost utility analyses.
鉴于治疗方法的进步,基于通用偏好的工具无法充分衡量乳腺癌(BrC)与健康相关的生活质量偏好。我们的总体目标是开发乳腺癌效用工具(BUI),这是一种基于BrC特异性偏好的工具。本研究描述了BUI项目的选择。共有408名来自不同BrC健康状态的患者完成了欧洲癌症研究与治疗组织(EORTC)生活质量核心问卷(QLQ-C30)和乳腺模块(BR45)。对于之前通过验证性因子分析评估的10个维度中的每一个,我们基于整体模型和项目拟合评估数据与Rasch模型的拟合度,包括阈值排序、项目残差、内拟合和外拟合、项目功能差异(年龄)和单维度性。对不拟合的项目进行迭代删除,并重新评估模型拟合度。从符合Rasch模型的项目中,我们根据患者和临床医生评定的项目重要性、项目阈值的广度和临床相关性,每个维度选择1个项目。7个维度的整体模型拟合良好,3个维度接近临界值。4个维度的区分指数可接受。以下项目的项目选择标准得到了最大化:1)身体功能(长时间行走困难),2)情绪功能(担忧),3)社会功能(干扰社交活动),4)疼痛(疼痛),5)疲劳(疲倦),6)身体形象(对自己的身体不满意),7)全身治疗副作用(脱发),8)性功能(对性的兴趣),9)乳腺症状(乳腺过度敏感),10)内分泌治疗症状(关节问题)。我们为BUI提出了10个项目。我们的下一步包括在确定BUI的偏好权重之前评估测量属性。
先前的验证性因子分析确定了欧洲癌症研究与治疗组织(EORTC)生活质量核心问卷(QLQ-C30)及其乳腺模块(BR45)的10个维度。在本研究中,我们根据与Rasch模型的拟合度、患者和临床医生评定的项目重要性、项目阈值的广度和临床相关性,每个维度选择1个项目。这些项目构成了未来乳腺癌效用工具(BUI)的核心。未来的BUI将是一种新型的基于乳腺癌特异性偏好的工具,可能会在临床决策和成本效用分析中更好地反映女性的偏好。